Bayer
100 Bayer Road
Whippany
New Jersey
07981
United States
Tel: 1-877-229-3727
Website: http://www.career.bayer.us/
Email: careersus@bayer.com
About Bayer
It all starts with a friendship between two men, plenty of natural curiosity and two kitchen stoves. Businessman Friedrich Bayer and dyer Johann Friedrich Weskott use these to conduct experiments and eventually discover how to make the dye fuchsine.
On August 1, 1863, they found the "Friedr. Bayer et. comp." company in Wuppertal-Barmen, a 19th century startup with tremendous potential.
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time.
Our goal is to create value for our customers, stockholders and employees, while also strengthening the company’s earning power. We are committed to operating sustainably and addressing our social and ethical responsibilities. Employees with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our purpose: Science for a better life.
Passion to innovate | Power to change
462 articles with Bayer
-
Increased Consumer Risks from Purchasing Erectile Dysfunction Medicine on the Gray Market Exposed in New Research
11/14/2018
Bayer and the National Consumers League release white paper that explores the risks consumers face when purchasing erectile dysfunction (ED) medicines from illegal online pharmacies and provides policy recommendations for increasing safe access to ED medicines.
-
Lannett Enters Into Distribution Agreement For Vardenafil Hydrochloride Tablets
11/1/2018
Launch Commenced; First-Time Generic Launch of Levitra®.
-
Genpact and Bayer to Co-innovate to Leverage Artificial Intelligence Capabilities for Patient Safety
11/1/2018
Genpact today announced it has signed a multi-year agreement with Bayer.
-
A prostate cancer drug jointly developed by healthcare giant Bayer and Finland-based Orion can slow the spread of the disease, according to late-stage study results announced early Wednesday.
-
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
10/24/2018
The safety and tolerability observed in the trial were consistent with previously published data on darolutamide.
-
Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types
10/21/2018
Median duration of response (mDOR) in primary dataset not reached after follow-up of 17.6 months(1)
-
Bayer U.S. Appoints Scott Partridge General Counsel
10/16/2018
Scott Partridge, former vice president of global strategy for Monsanto, now part of Bayer, has been named the company's U.S. General Counsel.
-
Apotheker Group Announces Launch of Life Sciences Executive Search and Advisory Services Firm
10/12/2018
Apotheker Group, Search and Advisory, Executive Search & Advisory firm specializing in the life sciences industry, is pleased to announce its official launch. The launch was celebrated recently at the Electric Room lounge at the Dream Downtown Hotel in NYC on the 4th of October. -
Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress
10/9/2018
Research presented includes expanded pivotal trial data set on pipeline compound larotrectinib for TRK fusion cancer across multiple tumor types in adult and pediatric patient
-
German company Bayer AG is laying off 227 staffers at its manufacturing plant in Berkeley, California. Most of the cuts took place on October 3.
-
More than 1,000 Bayer Employees Team Up and Volunteer Across America for Company's Annual Community Service Day
10/3/2018
Employees coast-to-coast will give back to their communities on October 12
-
MOHAP signs two MoUs with Astrazeneca and Bayer to provide free medicines to patients with critical illnesses
10/3/2018
Dr. Amin Al Amiri: the Programs are part of ministry's initiatives during ‘Year of Zayed’ to provide quality of care to patients
-
Movers and Shakers Oct. 1
10/1/2018
Here's a look at who shook things up in the world of pharma and biotech this week. -
Apotheker Group Executive Search and Advisory Services Firm Celebrates its Launch and Honors Recently Appointed ACMA Board of Governors
9/28/2018
Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.
-
Working Mother Names Monsanto, Now Part of Bayer, to its 2018 "100 Best Companies Lisr"
9/25/2018
Recognition Marks the Second Consecutive Year the Legacy Agriculture Company Is Honored for Its Parent-Friendly Policies
-
Following AbbVie Lawsuit, Government Scrutinizes Industry-Provided Drug Educational Support Services
9/21/2018
A federal investigation is underway into whether or not the nursing and other medical services provided by some pharmaceutical companies to doctor’s offices actually violate the law due to serving an illegal commercial service. -
Compugen Announces Clinical Milestone Payment in Cancer Immunotherapy Collaboration With Bayer Following Dosing of First Patient in BAY 1905254 Phase 1 Trial
9/20/2018
Compugen entitled to $7.8 million milestone payment
-
Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.
-
Bayer Animal Health and NeuroCycle Therapeutics sign global license agreement
9/12/2018
Bayer to strengthen its portfolio of products for companion animals with new allergy treatment options derived from NeuroCycle Therapeutics
-
TissUse establishes a liver-endocrine tissues multi-organ model for risk assessment with Bayer
9/10/2018
TissUse has signed a collaboration agreement with Bayer to develop a highly innovative liver-endocrine tissues assay using TissUse’s Multi-Organ-Chip (MOC) technology.